Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer
Status:
Active, not recruiting
Trial end date:
2029-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate efficacy and toxicity of either the combination of
docetaxel, trastuzumab sc and pertuzumab (arm A) or trastuzumab emtansin (arm B). Switch of
therapy to the opposite treatment alternative is applicable in case of lack of response after
two courses of treatment, or for medical reasons under exceptional circumstances (drug
reaction, other medical conditions) at any point. After termination of the primary treatment
follow-up for five years.
A translational subprotocol is a mandatory part of the study protocol, with exception for the
use of PET-CT evaluations.